As the Trump administration winds down its recent medical research funding initiatives, there have been ongoing concerns among scientists and administrators at the National Institutes of Health regarding Dr. Jay Bhattacharya’s level of autonomy as the director of the institution.
The government’s efficiency project, championed by Elon Musk to reduce costs, has impacted decisions related to the cancellation or postponement of research grants. Some initiatives have also been adversely affected by President Trump’s confrontation with universities over anti-Semitism. However, during a Senate committee hearing on Tuesday, Dr. Bhattacharya had a chance to clarify his influence at the NIH but opted not to take ownership of the institution’s longstanding fundraising efforts.
When questioned about the freeze on grant payments to Northwestern University, Dr. Bhattacharya remarked, “That occurred before my tenure,” referring to the Senate Appropriations Committee.
He emphasized that the proposal to cut the NIH budget to $18 billion (a nearly 40% reduction) stemmed from “congress-administrator collaboration,” and he refrained from elaborating on how these cuts might impact institutions.
Further funding cuts were necessitated by rising research costs—an action integrated into the administration’s 2026 budget proposal. Dr. Bhattacharya mentioned ongoing litigation, stating, “I don’t want to delve into it.”
Several Democrats on the committee expressed confusion regarding the decision-making process at the agency.
Senator Tammy Baldwin, a Democrat from Wisconsin, asked, “Who is withholding these funds?” citing evidence that the NIH reduced grants by billions compared to the previous year. “Is it you? Is it the OMB?” she inquired, referencing the Office of Management and Budget. “Who makes these decisions?”
Dr. Bhattacharya responded, “There are many various decisions. For instance, it was his choice to pivot from what is termed ‘politicized science,’ a phrase he previously used to describe research concerning diversity and equity issues. However, he asserted that restricting research funding at Harvard and other prominent institutions was in “collaboration with the administration.”
Senator Dick Durbin from Illinois reacted sharply after Dr. Bhattacharya distanced himself from the decisions regarding funding for the halted study at Northwestern.
An email from an NIH staff member in mid-April, weeks post Dr. Bhattacharya’s confirmation, instructed employees to refrain from issuing grants to Northwestern and various other universities, without notifying them of the reasons for the funding freeze.
“The buck stops at your office,” Durbin said to Dr. Bhattacharya. “Don’t shift the blame.”
The Trump administration’s plans for significant spending cuts at the agency have drawn criticism from both parties, including Republican Senator Susan Collins from Maine.
She told Dr. Bhattacharya that the proposed cuts are “very intrusive,” warning that they could delay or halt the development of effective treatments for diseases like Alzheimer’s, cancer, and type 1 diabetes, potentially leaving the U.S. “lagging behind China.”
In response, Dr. Bhattacharya noted that the NIH is engaged in Alzheimer’s and other disease research and will collaborate with lawmakers to address “the health needs of all Americans.”
The director hinted at a possible agreement between the Trump administration and major universities regarding the restoration of medical research funding, yet he did not offer details on the prospects of such an agreement or its prerequisites. “I am very hopeful for a resolution with the universities regarding the grants that have been suspended,” he stated.
In recent years, the NIH has abruptly terminated over 1,300 grant awards and postponed funding for more than 1,000 additional projects. On Monday, numerous NIH employees signed a letter asserting that these actions were dictated by ideological biases and lacked input from scientific staff, effectively suppressing research on health disparities, COVID-19, climate change, and the impacts on sexual health.
On Tuesday, Dr. Bhattacharya stated that scientists have established a process for appealing against funding reductions, and the agency intends to file appeals within weeks.
Source: www.nytimes.com
